Cytokine Release Syndrome Induced by Pembrolizumab for Metastatic Anal Melanoma
Cytokine release syndrome (CRS) is a rare systemic inflammatory response that can be triggered by certain drugs and infections, commonly diagnosed at a disseminated stage, leading to poor prognosis. This has been well described following chimeric antigen receptor T-cell (CAR-T) therapy but has rarel...
Saved in:
| Main Authors: | Erica Martel, Shijia Li, Mayssaa Hoteit, Zubin Bham |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/crh/5444075 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report
by: Chul Kim, et al.
Published: (2021-07-01) -
Combined IVIG and High‐Dose Systemic Corticosteroids for the Management of Pembrolizumab‐Induced Cytokine Release Syndrome in Lung Adenocarcinoma
by: Cheng‐Yin Liu, et al.
Published: (2025-05-01) -
Fatal Outcome of Pembrolizumab-Related Cytokine Release Syndrome in a Patient With Concurrent Parainfluenza Infection
by: Wei Hung Hung, et al.
Published: (2025-02-01) -
Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
by: Yuan Yao, et al.
Published: (2025-02-01) -
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
by: Alessio Cortellini, et al.
Published: (2018-01-01)